NO981961L - FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon - Google Patents

FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon

Info

Publication number
NO981961L
NO981961L NO981961A NO981961A NO981961L NO 981961 L NO981961 L NO 981961L NO 981961 A NO981961 A NO 981961A NO 981961 A NO981961 A NO 981961A NO 981961 L NO981961 L NO 981961L
Authority
NO
Norway
Prior art keywords
combination
methylethyl
pharmaceutical composition
concentration control
lipid concentration
Prior art date
Application number
NO981961A
Other languages
English (en)
Norwegian (no)
Other versions
NO981961D0 (no
Inventor
Thomas M A Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21719566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO981961(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO981961D0 publication Critical patent/NO981961D0/no
Publication of NO981961L publication Critical patent/NO981961L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO981961A 1995-11-02 1998-04-30 FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon NO981961L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US615595P 1995-11-02 1995-11-02
PCT/US1996/015854 WO1997016184A1 (en) 1995-11-02 1996-10-02 Method and pharmaceutical composition for regulating lipid concentration

Publications (2)

Publication Number Publication Date
NO981961D0 NO981961D0 (no) 1998-04-30
NO981961L true NO981961L (no) 1998-05-04

Family

ID=21719566

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981961A NO981961L (no) 1995-11-02 1998-04-30 FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon

Country Status (27)

Country Link
US (3) US6124309A (hu)
EP (1) EP0858336B1 (hu)
JP (1) JPH11515025A (hu)
KR (2) KR20040029459A (hu)
CN (2) CN1217656C (hu)
AR (1) AR004527A1 (hu)
AT (1) ATE348607T1 (hu)
AU (1) AU720853B2 (hu)
BG (1) BG64018B1 (hu)
BR (1) BR9611410A (hu)
CZ (1) CZ127198A3 (hu)
DE (1) DE69636783T2 (hu)
EA (1) EA000514B1 (hu)
ES (1) ES2279526T3 (hu)
GE (1) GEP20001898B (hu)
HK (1) HK1016509A1 (hu)
HU (1) HUP9901865A3 (hu)
IL (1) IL123902A (hu)
IS (1) IS4720A (hu)
NO (1) NO981961L (hu)
NZ (2) NZ512484A (hu)
PL (1) PL186714B1 (hu)
RO (1) RO120816B1 (hu)
SK (1) SK284142B6 (hu)
UA (1) UA46069C2 (hu)
WO (1) WO1997016184A1 (hu)
ZA (1) ZA969187B (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
EP1514543A1 (en) * 1997-08-29 2005-03-16 Pfizer Inc. Combination therapy comprising atorvastatin and an antihypertensive agent
EP1063991A1 (en) * 1998-03-17 2001-01-03 Warner-Lambert Company Llc Statin-matrix metalloproteinase inhibitor combinations
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
HUP0103648A3 (en) * 1998-09-30 2003-10-28 Warner Lambert Co Method for preventing or delaying catheter-based revascularization
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
AU7717500A (en) * 1999-09-30 2001-04-30 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
EP1092432A1 (fr) * 1999-10-15 2001-04-18 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. (S.C.R.A.S.) Composes anti-ischemiques
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
BR0113523A (pt) * 2000-09-01 2004-06-29 Sankyo Co Composição farmacêutica, kit, e, usos de n-(1-octil-5-carboxi-metil)-4,6-dimetil-indolin-7-il)-2,2-d imetil-propanamida ou um seu sal farmacologicamente aceitável, e de uma composição
JP2004529069A (ja) 2000-10-11 2004-09-24 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理用のエーテル化合物及び組成物ならびに関連する使用
BR0114619A (pt) 2000-10-11 2005-12-13 Esperion Therapeutics Inc Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
AU1313602A (en) 2000-10-11 2002-04-22 Esperion Therapeutics Inc Ketone compounds and compositions for cholesterol management and related uses
CN1479721A (zh) 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
US7304093B2 (en) * 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US20040204502A1 (en) * 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20040192771A1 (en) * 2001-10-11 2004-09-30 Dasseux Jean-Louis Henri Ether compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) * 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
WO2003077896A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Drug combination therapy
EP1495034A2 (en) * 2002-04-10 2005-01-12 Esperion Therapeutics, Inc. Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
JP4187141B2 (ja) * 2002-04-12 2008-11-26 興和株式会社 新規なトロンボモジュリン発現促進剤
PT2404890T (pt) * 2003-01-23 2017-10-23 Esperion Therapeutics Inc Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
RU2358734C2 (ru) 2003-08-29 2009-06-20 Кова Ко., Лтд. Способ стабилизации бляшки с высоким содержанием липидов и способ профилактики ее разрушения
CA2546079A1 (en) * 2003-11-17 2005-05-26 Toyo Shinyaku Co., Ltd. Lipometabolism improver containing pine bark extract
EP1701931B1 (en) 2003-12-24 2018-10-10 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
AU2005235306B2 (en) * 2004-04-19 2008-08-21 Loma Linda University Composition and method of decreasing renal ischemic damage
TW200605890A (en) * 2004-07-28 2006-02-16 Sankyo Co Pharmaceutical compositions for inhibiting arteriosclerosis
CA2585623C (en) * 2004-10-27 2012-06-05 Daiichi Sankyo Company Limited Ortho-substituted benzene derivatives
TW200619204A (en) * 2004-12-10 2006-06-16 Kowa Co Method for reduction, stabilization and prevention of rupture of lipid rich plaque
AU2006313430B2 (en) * 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
AU2007245410A1 (en) 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
US20130254787A1 (en) 2006-05-02 2013-09-26 Invidi Technologies Corporation Method and apparatus to perform real-time audience estimation and commercial selection suitable for targeted advertising
US20070269503A1 (en) * 2006-05-16 2007-11-22 James Walter Burgess Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
CN103274985B (zh) * 2010-12-03 2016-03-09 上海科州药物研发有限公司 一种阿托伐他汀氨基酸盐
US8586527B2 (en) * 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
DK2771003T3 (en) 2011-10-28 2017-07-17 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver disease
CN103304496A (zh) * 2012-03-08 2013-09-18 南京工业大学 一种合成申嗪霉素方法
WO2013171100A1 (en) 2012-05-16 2013-11-21 Joachim Hans Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors
JP6940411B2 (ja) 2015-03-13 2021-09-29 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN112437765A (zh) 2019-06-21 2021-03-02 艾斯柏伦治疗公司 贝派地酸的盐形式及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
CA2003478A1 (en) * 1988-12-12 1990-06-12 Leonard G. Dennick Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2048395A1 (en) * 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
WO1993002048A1 (en) 1991-07-23 1993-02-04 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
AU5538794A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Biologically active compounds and process therefor
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
AU1095695A (en) * 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物

Also Published As

Publication number Publication date
PL186714B1 (pl) 2004-02-27
US6124309A (en) 2000-09-26
EP0858336B1 (en) 2006-12-20
EP0858336A1 (en) 1998-08-19
AR004527A1 (es) 1998-12-16
HUP9901865A2 (hu) 1999-10-28
RO120816B1 (ro) 2006-08-30
IS4720A (is) 1998-04-17
HUP9901865A3 (en) 2000-06-28
ZA969187B (en) 1997-05-29
EA199800420A1 (ru) 1998-10-29
ES2279526T3 (es) 2007-08-16
NO981961D0 (no) 1998-04-30
ATE348607T1 (de) 2007-01-15
KR20040029459A (ko) 2004-04-06
CN1201389A (zh) 1998-12-09
UA46069C2 (uk) 2002-05-15
CN1679953A (zh) 2005-10-12
HK1016509A1 (en) 1999-11-05
BR9611410A (pt) 1999-01-05
IL123902A (en) 2003-01-12
JPH11515025A (ja) 1999-12-21
SK55798A3 (en) 1999-06-11
EA000514B1 (ru) 1999-10-28
IL123902A0 (en) 1998-10-30
US6093719A (en) 2000-07-25
KR19990067270A (ko) 1999-08-16
NZ319906A (en) 2000-02-28
AU720853B2 (en) 2000-06-15
KR100449604B1 (ko) 2004-11-16
DE69636783D1 (de) 2007-02-01
BG64018B1 (bg) 2003-10-31
DE69636783T2 (de) 2007-10-18
PL326365A1 (en) 1998-09-14
AU7253996A (en) 1997-05-22
NZ512484A (en) 2003-02-28
WO1997016184A1 (en) 1997-05-09
GEP20001898B (en) 2000-01-05
SK284142B6 (sk) 2004-10-05
CZ127198A3 (cs) 1998-12-16
US6143755A (en) 2000-11-07
BG102417A (en) 1999-01-29
CN1217656C (zh) 2005-09-07

Similar Documents

Publication Publication Date Title
NO981961L (no) FremgangsmÕte og farmas÷ytisk blanding for regulering av lipidkonsentrasjon
MX9702204A (es) Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].
Ginsberg Effects of statins on triglyceride metabolism
NO20013161L (no) Preparater av ileum-gallesyretransportinhibitorer og kolesterylesteroverföringsproteininhibitorer for kardiovaskul¶reindikasjoner
EE9400341A (et) Kolesterooli biosünteesi inhibiitori ja kolesterooli absorptsiooni ß-laktaaminhibiitori kombinatsioon
NO20100214L (no) Preparat for a redusere LIPG ekspresjon hos en pasient og anvendelsen av dette
DE69628874D1 (de) Verwendung eines HMG CoA-Reduktase Inhibitors zur Vorbeugung eines zweiten Herzanfalls
FI951218A0 (fi) Menetelmä kokonaiskolesterolin ja matalatiheyksisen lipoproteiinikolestrolin pitoisuuksien pienentämiseksi veressä
DE69115909D1 (de) Verwendung von Phospholipiden zur Herstellung eines topischen Arzneimittels zur Beinflussung des Serumcholesterinspiegels
Carson Tissue factor (coagulation factor III) inhibition by apolipoprotein A-II.
Zieve et al. Post-heparin phospholipase and post-heparin lipase have different tissue origins
Bergstrom et al. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin
DE69429816D1 (de) C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
Andreassen et al. Changes in Lp (a) lipoprotein and other plasma proteins during acute myocardial infarction
ATE353957T1 (de) Verwendung von lezithin-cholesterin- azetyltransferase für die behandlung von atherosklerose
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
Cromwell et al. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
CA2233558A1 (en) Method and pharmaceutical composition for regulating lipid concentration
Stohler et al. Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia
Pioruńska-Stolzmann et al. The influence of simvastatin on lipase and cholesterol esterase activity in the serum of men with coronary heart disease
Bevilacqua et al. Effects of fluvastatin on lipids profiles and t-PA mass concentration in coronary patients with primary hypercholesterolemia and high LP (a)
Hadjiisky et al. Effect of pravastatin, a HMG CoA reductase inhibitor, on blood lipids and aortic lipidosis in cholesterol-fed White Carneau pigeons
Suckling Anti-atherosclerotics-Bile acid sequestrants, cholesterol absorption and fibrates
La Belle et al. Quality of life in a 6-week study of simvastatin vs pravastatin
Kleinfeld The role of free fatty acids in CTL-target cell interactions